Background: Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension. Previous studies have shown nGR-related hypertension is normalized by neonatal leptin (nLep) and exacerbated by psychological stress. With recent studies linking leptin and angiotensin signaling, we hypothesized that nGR-induced nLep deficiency increases adult leptin sensitivity; leading to leptin-or stressinduced hypertension, through a pathway involving central angiotensin II type 1 receptors. Methods: We randomized mice with incipient nGR, by virtue of their presence in large litters, to vehicle or physiologic nLep supplementation (80 ng/g/d). Adult caloric intake and arterial pressure were monitored at baseline, during intracerebroventricular losartan infusion and during systemic leptin administration. results: nGR increased leptin-triggered renal sympathetic activation and hypertension with increased leptin receptor expression in the arcuate nucleus of the hypothalamus; all of those nGR-associated phenotypes were normalized by nLep. nGR mice also had stress-related hyperphagia and hypertension, but only the stress hypertension was blocked by central losartan infusion. conclusion: nGR leads to stress hypertension through a pathway that involves central angiotensin II receptors, and nGR-associated leptin deficiency increases leptin-triggered hypertension in adulthood. These data suggest potential roles for preservation of neonatal growth and nLep supplementation in the prevention of nGR-related hypertension.
W
orldwide, nearly 16% of all infants are born with low birth weight (1) . Premature delivery and fetal growth restriction, the two predominant causes of low birth weight, both pose numerous and at times insurmountable challenges to the developing infant, including profound nutritional deficiencies. By the time premature infants reach 36 wk postmenstrual age, nearly 90% have developed neonatal growth restriction (nGR) and up to 70% have elevated arterial pressure (2, 3) . In one of the largest studies to date, Johansson and colleagues assessed blood pressure in 329,495 military conscripts and revealed a strong inverse association between birth weight and adult blood pressure, but the effect of intrauterine growth restriction was overshadowed by the consequences of preterm birth (4) . Specifically, the odds of hypertension, adjusted for both birth weight and current body mass index, increased by 25, 48, and 93% in subjects born [4] [5] [6] [7] [8] [9] [10] [11] , and 12-16 wk prematurely, respectively (4) .
As an adipose-derived neurotrophic hormone that is intimately involved in cardiometabolic regulation (5) , leptin has emerged as a putative agent in both the inception and the propagation of programmed cardiovascular and metabolic dysfunction (6) . Leptin readily crosses the placenta and typically exerts neurotrophic effects in the third trimester of fetal development. Preterm delivery abruptly terminates transplacental leptin delivery and preterm infants face the need to grow and develop in the presence of dramatic leptin deficiency (7, 8) .
Of those who survive this neonatal insult, the risk of adult cardiometabolic deterioration increases dramatically in the presence of adult obesity (9) . Leptin levels strongly correlate with adult adiposity and investigations have revealed an important role for leptin in murine and human hypertension (5, 10) , with relevant pathways including hypothalamic signaling, coactivation of the renin-angiotensin system and renal sympathetic nerve activation (11, 12) .
In mice, the first 2 wk of life model the third trimester of human neurodevelopment (13) . Our previous investigations assessing the impact of naturally-occurring nGR revealed that nGR mice share many of the phenotypes described in former preterm infants, including leptin deficiency, postnatal growth restriction, neuropsychiatric impairment, and stress-evoked hypertension (14) (15) (16) . Follow-up studies demonstrated normalization of brain morphology, neurodevelopment, and stress-associated (tail cuff) hypertension following neonatal leptin (nLep) supplementation (14, 16) . We speculated that
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Articles nGR programs a range of adverse developmental outcomes by persistently upregulating hypothalamic leptin responsiveness.
With recent evidence linking leptin with the hemodynamic response to psychological stress and the central renin-angiotensin system (11, 12) , we sought to test the hypothesis that nGR leads to stress-or leptin-evoked hypertension in a pathway that involves the angiotensin II type 1 receptor (AT 1 R). In order to isolate the cardiovascular phenotypes programmed in nGR mice, we incorporated an extensive array of advanced physiologic methods, including carotid radiotelemetry, renal sympathetic nerve recordings and intracerebroventricular infusions (Figure 1) . Once the nGR-induced phenotypes were identified, we tested the rigorous hypothesis that nGR mice not only did not significantly differ from control mice (either because of similarity or a lack of statistical power), but were statistically equivalent to control mice with cardiovascular phenotypes constrained below the levels seen in nGR mice that had not received nLep supplementation.
RESULTS
By definition, nGR mice had reduced weanling weights, and this was independent of nLep therapy ( Table 1) . Overall 10.3% (20 of 195) male mice fostered in standardized litters of 6 pups developed nGR, as defined by a weanling weights below our historic 10th percentile cut-off of 7.1 g. The occurrence of nGR increased to 40.2% (131 of 326) for mice fostered in litters of 12 pups. As adults, nGR mice remained smaller than controls, and the null hypothesis that nGR and control mice did not differ was rejected (P < 0.01). However, the 90% confidence interval for the difference in means between nGR-nLep and control mice (−4.3 to 0.5 g) extended beyond the mean difference between nGR and control mice (−4.0 g), leading to acceptance of the null hypothesis that control and nGR-nLep supplemented mice may differ as much as control and nGR mice that did not receive nLep ( Table 1) . Beyond body weight, baseline ambulatory blood pressure, heart rate, and locomotor activity were not significantly altered by nGR ( Table 1) . Comparing the two cohorts of mice that subsequently underwent different experimental protocols (Figure 1) , adult weight and hemodynamic parameters were independent of whether the mice were fostered by their birth dam without neonatal injections (cohort 1) or cross-fostered by an adoptive dam with neonatal injections (cohort 2) (data not shown).
Given investigations revealing growth restriction-associated increases in sympathetic tone (17) , mice were subsequently challenged with a series of autonomic antagonists. Consistent with a predominance of resting cardiac sympathetic activation in mice, scopolamine did not significantly alter either blood pressure or heart rate, while the ganglionic blocker chlorisondamine caused a dramatic reduction in both parameters, independent of nGR status (Figure 2) . Finally, the α 1 -adrenergic receptor selective antagonist prazosin elicited a comparable hypotensive response in both nGR and control mice (Figure 2) .
To begin assessment of central autonomic regulation, intracerebroventricular (icv) catheters were placed and hemodynamics were measured during psychologic challenge. Compared to control mice, nGR mice had an exaggerated hypertensive response to cage switch stress, and icv losartan significantly reduced the stress-evoked hypertension displayed by nGR mice (Figure 2) . Independent of nGR status, cage-switch stress led to a near doubling corticosterone levels (control baseline 137 ± 23 ng/ml vs. stressed 250 ± 19 ng/ ml, P < 0.01, n = 7; nGR baseline 132 ± 13 ng/ml vs. stressed 224 ± 24 ng/ml, P < 0.01, n = 6), confirming the presence of a stress response, but suggesting the exaggerated response seen in nGR mice was not driven by a programmed change in corticosterone production. Utilizing the 10th percentile cutoff, neonatal growth restriction (nGR) pups were identified by a weight <7.1 g at 3 wk. Once they reached 17 wk, a radiotelemetry-enabled carotid artery catheter was placed (art). After 1 wk of recovery, hemodynamics were measured throughout a 60 h baseline window (BL). This was followed by a series of four randomized once daily intraperitoneal injections including vehicle alone, scopolamine, chlorisondamine, and prazosin (IP). Mice then underwent icv cannulation followed in 48 h by placement in a stress-evoking metabolic cage (S), first without losartan pretreatment and then 24 h later, with losartan pretreatment. The second cohort of mice (b) were fostered in litters of 6 or 12 pups with those in litters of 12 randomized to either vehicle or nLep on days 4 to 14. The same weight-based criteria were utilized to distinguish control and nGR mice and carotid catheters were again placed and BL readings were obtained. This time, the BL recordings were immediately followed by icv cannulation for 14 d continuous infusion of artificial cerebrospinal fluid or losartan. After 48 h recovery, new BL recordings were obtained, followed the next day by S recordings that were in turn followed by recordings during ip challenge with vehicle or leptin. Finally, on days 10 to 13 of icv infusion, the mice received twice daily intraperitoneal leptin (Lep). Additional mice fostered by the second breeding approach did not undergo radiotelemeter implantation, but rather were used for sympathetic recordings or gene expression analysis. The second cohort of mice was then utilized to determine whether physiologic nLep and/or continuous AT 1 R antagonist administration protect nGR mice from stress-evoked hypertension. Once again nGR mice receiving only an infusion of artificial cerebrospinal fluid (aCSF) weighed less than their control counterparts (mean difference of −4.6 g, Figure 3a ), and that was again not definitively prevented by nLep (90 percent confidence interval for the mean difference between nGR-nLep and control: −9.4 to 0.2 g). Unexpectedly, icv cannulation with infusion of either aCSF or losartan dramatically increased the food intake of nGR-vehicle mice (Figure 3b) , raising the possibility of increased stress reactivity. Independent of aCSF vs. losartan administration, both control and nGR mice lost weight during twice daily leptin administration (Figure 3a) , and that was associated with a leptin-induced anorexia in all but nGR mice receiving icv losartan (Figure 3b) .
Regarding hemodynamic outcomes, nGR and low dose central losartan infusion had no significant effect on resting blood pressure, heart rate, or locomotor activity beyond a mild losartan-induced decrease in systolic blood pressure that was exclusively seen in control mice ( Table 2) . A significant interaction between nGR and losartan administration influenced the hypertensive response to stress (Figure 4) . Compared to the corresponding controls (Figure 4) , nGR mice receiving aCSF had an exaggerated hypertensive response to placement in the metabolic cage (mean difference of 3.7%), and that stress response was significantly suppressed by icv losartan, but not normalized to equivalence by nLep (90 percent confidence interval for the mean difference between nGR-nLep and control: −10 to 6.7%).
To further test our hypothesis that nGR-associated nLep deficiency increases adult leptin responsiveness through a pathway involving the AT 1 R, we went on to assess the independent and interactive effects of nGR and central losartan administration on the hemodynamic responses evoked by leptin. Unlike control mice, nGR-vehicle mice had an exaggerated hypertensive response to the initial dose of exogenous leptin (mean difference in systolic, mean and diastolic pressures after leptin vs. vehicle administration of 10.5, 9.2, and 8.2 mmHg, respectively), and those . Hemodynamic responses to autonomic blockers or psychological stress. Mean blood pressure (MBP, a) and heart rate (HR, b) were measured 20-50 min following randomized intraperitoneal injections of normal saline (vehicle, 10 ml/kg), scopolamine (2 mg/kg), the ganglionic blocker chlorisondamine (GB, 2.5 mg/kg), or prazosin (1 mg/kg). Following those injections, an icv catheter was placed and measurements were obtained during placement in a stress-evoking metabolic cage, without and with losartan pretreatment (20 µg icv). For both control (solid bars) and neonatal growth restriction (nGR) mice (open bars), GB lowered MBP and HR while prazosin lowered MBP and placement in a metabolic cage increased HR. Compared to control mice, nGR mice had stressevoked hypertension that was blocked by losartan. *P < 0.05 vs. control, **P < 0.05 vs. normal saline, †P < 0.05 vs. no losartan; n = 11 control and 7 GR (1 control mouse did not receive the intraperitoneal injections; 2 control mice did not have post-icv losartan data including 1 mouse that did not undergo icv cannulation and 1 mouse that died during icv injection; 3 GR mice did not have post-icv losartan data including 1 mouse that did not undergo cannulation, 1 mouse that died during icv injection and 1 mouse that lost pulsatile arterial pressure readings with a MBP consistently < 60 mmHg following icv injection). Articles responses were absent in nGR mice that were receiving icv losartan ( Table 3) . The hemodynamic responses of nGRnLep mice to exogenous leptin were diametrically opposed to the responses seen in nGR-vehicle mice and the systolic blood pressure response was statistically equivalent to the response of control mice (confidence intervals for the difference between control and nGR-nLep mice for systolic, mean, and diastolic pressures were −9.0 to 1.0, −14.6 to 0.9, and −17.4 to 2.3) ( Table 3) .
To determine if the pressor response to leptin is sustained during ongoing leptin administration, mice were next given twice daily leptin for 4 consecutive days. Compared to the baseline results obtained during icv infusion of aCSF or losartan in the absence of exogenous leptin, sustained leptin administration only elicited a mild increase in mean and diastolic blood pressure among control mice receiving icv losartan infusion ( Table 4 ). This contrasts with the persistent leptin-induced anorexia seen in nGR-vehicle mice during that same treatment period (Figure 3b) .
In order to further evaluate the role of acute leptin exposure on nGR-associated sympathetic activation, renal sympathetic nerve recordings were obtained during intravenous leptin administration. Throughout the second hour of recording, leptin-evoked changes in renal sympathetic nerve activity (RSNA) were significantly increased in nGR mice (Figure 5a , mean differences vs. control of 23 to 30%). The leptin-evoked RSNA of nGR-nLep mice were again diametrically opposed to the responses seen in nGRvehicle mice and statistically equivalent to the responses of control mice at 60 and 75 min (Figure 5a , confidence intervals for the difference between control and nGR-nLep mice ranged from −22 to 15 at 60 min to −54 to 13 at 120 min). During the RSNA recordings, blood pressure consistently decreased (Figure 5b ) and heart rate consistently increased (Figure 5c ). The absence of leptin-triggered hypertension during anesthetized RSNA recording is consistent with results previously reported with this method in mice (18) . Given the possibility that leptin-dependent NOS activation may partially buffer the hemodynamic effects of leptin, the nitric oxide synthase antagonist L-NAME was administered at the end of the protocol. L-NAME rapidly and dramatically increased arterial pressure with an exaggerated hypertensive response seen in nGR mice (Figure 5d , mean difference vs. control at 3 min: 37%) that was not normalized by nLep (confidence interval for the difference between control and nGR-nLep mice: 5.1 to 45%).
Precision biopsies of the hypothalamic regions that are critical in mediating leptin's hemodynamic effects were obtained and both LepR and AT 1 R mRNA expression were analyzed by qPCR. Unlike expression in the ventromedial hypothalamus, LepRb expression in the arcuate nucleus of the hypothalamus (ARC) was significantly increased in nGR mice (Figure 6 , mean difference vs. control: 86%), and this was normalized by nLep (confidence interval for the difference between control and nGR-nLep mice: −53 to 62%). There were no corresponding alterations in the expression of either the signaling-deficient short form of the leptin receptor (LepRa) or the AT 1 R (Figure 6) . (% baseline) 100 ± 1 99 ± 3 102 ± 2 100 ± 1 98 ± 2 95 ± 3 HR (bpm) 569 ± 17 555 ± 10 576 ± 5 591 ± 9 574 ± 16 594 ± 10 (% baseline) 103 ± 2 101 ± 2 101 ± 1 102 ± 1 103 ± 2 103 ± 1 Activity (au) 7.0 ± 0.8 4.9 ± 0.4 5.9 ± 0.9 6.2 ± 0.9 5.2 ± 0.4 6.0 ± 0.6 (% baseline) 149 ± 24 102 ± 18 116 ± 27 117 ± 7 120 ± 6 127 ± 17 *P < 0.01 vs. control. ** P < 0.01 vs. aCsF. aCsF, artificial cerebrospinal fluid; DBP, diastolic blood pressure; hR, heart rate; MBP, mean blood pressure; nGR, neonatal growth restriction; sBP, systolic blood pressure. Articles Peotta et al.
DISCUSSION
The inverse relationship between growth through 2 y and blood pressure in adulthood is a prototypic example of undernutrition during a critical window of development predisposing individuals to adult disease (19) . Animal models have been essential in the identification of the pathways that lead to programmed hypertension and may be amenable to therapeutic intervention. Among the potential interacting pathways, an important role for angiotensin receptor activation has been suggested in studies from diverse programming models. Global maternal undernutrition directly enhances cardiovascular responses to angiotensin II in the rat (20) . Likewise, maternal dexamethasone enhances the blood pressure response of adult sheep to icv angiotensin II and central losartan normalizes the programmed hypertension (21) . Our present investigations are the first we are aware of that investigated the interaction between leptin and angiotensin receptors in the programming of central cardiovascular regulation. We have significantly extended our earlier investigations showing that perinatal growth restriction leads to reduced adult weight-and stress-related hypertension (22) . Our present studies have identified associations between increased ARC leptin receptor expression and heightened stress or leptin-evoked blood pressure responses in nGR mice. The presence of relatively normal ambulatory blood pressure with exaggerated responses to psychological stress is consistent with human epidemiological data, as well as our prior investigations utilizing a stress-evoking tail cuff blood pressure monitoring system (23) . While previous studies have shown losartan potently inhibits psychological stressinduced hypertension (24) , the additional finding that central losartan administration decreases the response of nGR-vehicle mice to systemically administered leptin is unique. The increase in nGR-vehicle mouse food intake observed following icv cannulation was dramatic and may be related to the stress associated with the procedure. If this is the case, stress-induced hyperphagia may contribute to the increased central adiposity seen in a subpopulation of growth-restricted individuals, (25) which otherwise remain smaller than their normal birth weight peers (26) .
Beyond the ability of central AT 1 R blockade to prevent the development of stress-evoked hypertension, AT 1 R inhibition interfered with the hypertension evoked by leptin, but not the (% vehicle) 104 ± 4 100 ± 6 110 ± 2* 98 ± 3 93 ± 4 99 ± 2 HR (bpm) 540 ± 11 558 ± 15 571 ± 16 552 ± 14 544 ± 25 584 ± 10 (% vehicle) 104 ± 5 97 ± 3 108 ± 1 96 ± 2** 91 ± 3 102 ± 2 *P < 0.05 vs. vehicle. **P < 0.05 vs. aCsF. †P < 0.05 for equivalence to control. aCsF, artificial cerebrospinal fluid; DBP, diastolic blood pressure; hR, heart rate; MBP, mean blood pressure; nGR, neonatal growth restriction; sBP, systolic blood pressure. (% baseline) 97 ± 1 102 ± 2** 100 ± 2 100 ± 1 95 ± 3 96 ± 2 DBP (mmHg) 95 ± 3 99 ± 2 93 ± 2 94 ± 2 87 ± 4 88 ± 3 (% baseline) 97 ± 1 103 ± 2** 98 ± 1 101 ± 1 94 ± 3 97 ± 2 HR (bpm) 558 ± 6 554 ± 8 569 ± 11 583 ± 5* 566 ± 17 575 ± 8 (% baseline) 98 ± 2 100 ± 2 99 ± 2 97 ± 1 99 ± 2 97 ± 2 *P < 0.05 vs. control. **P < 0.05 vs. Baseline. aCsF, artificial cerebrospinal fluid; DBP, diastolic blood pressure; hR, heart rate; MBP, mean blood pressure; nGR, neonatal growth restriction; sBP, systolic blood pressure. , and heart rate (HR, c) were simultaneously recorded following intravenous leptin administration. After the 2 h recordings, the nitric oxide synthase inhibitor L-NAME was administered and SBP was monitored an additional 10 min (d). Compared to control mice (black symbols, n = 12), neonatal growth restriction (nGR) mice (white symbols, n = 11) but not nGR-nLep mice (gray symbols, n = 4) had exaggerated RSNA responses to leptin. *P < 0.05 vs. control, **P < 0.05 for equivalence to control. Articles anorexia response to leptin, suggesting alternative pathways are involved in leptin's cardiovascular and metabolic effects (27) . Because leptin-induced RSNA is known to be dependent on downstream AT 1 R signaling (12), we did not investigate the effect of losartan on leptin-evoked RSNA in the present study. Given investigations in humans suggesting increased sympathetic tone and heightened stress reactivity in growth-restricted individuals (17, 28) , we investigated the effects of nGR with or without nLep administration on adult leptin-evoked RSNA. nGR mice that did not receive nLep had an increased RSNA response within 2 h of leptin administration. Throughout that time, all mice became progressively hypotensive and tachycardic. Those hemodynamic changes are consistent with the findings previously reported in mice that received icv leptin (12) . While the declining blood pressures were potentially a manifestation of prolonged anesthesia, we were intrigued by publications showing leptin upregulates vascular nitric oxide synthase to buffer the development of hypertension that would be expected from parallel sympathetic activation (29) . Our data demonstrating a gradual decrease in blood pressure during RSNA recording followed by a rapid and robust increase in arterial pressure after L-NAME administration are consistent with leptin-triggered nitric oxide production in control and nGR mice. Further studies are needed to elucidate whether the relative hypertension seen in nGR mice following leptin plus L-NAME is a reflection of the increased RSNA or an increased reliance on the vasodilatory effects of nitric oxide. Our prior investigations in complementary nGR models support the presence of enhanced vascular nitric oxide-mediated vasodilatation in otherwise hypertensive mice (30) . It is possible that exaggerated nitric oxide production attenuated the response of nGR mice to prolonged leptin administration; further investigation is needed to determine if that possible compensatory response is lost with aging, obesity, or other mediators of endothelial dysfunction. Additional investigations, including sympathetic blockade or baroreceptor denervation, are likewise needed to more definitively identify sympathetic activation as a requisite for nGR-related hypertension.
Taken together, our data support a critical interaction between leptin and central AT 1 R in programmed cardiovascular dysregulation. Regarding brain-site-specific regulation, studies in transgenic mice lacking leptin receptors within the ARC have solidified the prime importance of the ARC in leptin's sympathetic and pressor effects (31) . Among leptinresponsive neuronal regions, the ARC is also exquisitely sensitive to environmental modulation of leptin sensitivity (32) , perhaps explaining the selective alteration in leptin receptor mRNA expression we noted within the ARC in the current studies. While intravenous administration was utilized to determine the physiologically relevant effects of systemically delivered leptin, additional mechanistic studies could include further assessment of leptin receptor splice variants and icv leptin administration to determine if the increased response seen in nGR mice is related to enhanced access to central leptin receptors. In addition to leptin, insulin signaling within the ARC plays an important role in diabetesrelated sympathetic activation (33) . With peripheral insulin resistance common in former growth-restricted individuals, the potential for selective central insulin sensitization merits further investigation.
nLep replacement is a more targeted therapy than global overnutrition and may serve to rescue cardiovascular health while avoiding the increased risk of obesity and obesity-related hyperleptinemia plus endothelial dysfunction that occurs with hypercaloric nutrition. However, leptin remains a pleiotropic hormone that exerts diverse effects in a coordinated response to maintain cardiometabolic homeostasis. Greater understanding of leptin's signaling partners has been needed to fine-tune its therapeutic utilization, and our investigations were designed with that goal in mind. Preterm and growth-restricted term infants have significant reductions in circulating leptin levels, and both populations may benefit from early supplementation targeted to leptin level normalization (34, 35) . Our results may translate most directly to the premature population who must undergo critical phases of neurodevelopment without the benefit of transplacental leptin. Exogenous leptin administration has already been shown to elicit neurotrophic effects in growth-restricted piglets and genetically leptin-deficient humans (36, 37) . Future studies are necessary to determine if nLep can improve upon the guarded cardiovascular prognosis of premature infants. Expression within the ARC and ventromedial hypothalamus (VMH) of the leptin receptor (a, long-form: LepRb; short-form: LepRa) and AT 1A R (b) was determined for adult control (rhombi or black bars, n = 15 for ARC, n = 14 for VMH), nGR (circles or white bars, n = 7 for ARC, n = 6 for VMH) and nGRnLep mice (triangles or gray bars, n = 13 for ARC, n = 12 for VMH). Four values that were greater than 1.5 times the span of the interquartile range outside of the interquartile range were a priori excluded as statistical outliers (solid symbols). Relative mRNA expression was then compared by the 2 -ΔΔCT method, setting control expression at 100% (c and d). Compared to control mice LepRb mRNA expression was increased in the ARC of nGR but not nGR-nLep mice. *P < 0.05 vs. control, **P < 0.05 for equivalence to control. 
